Nucleotide-based prodrugs
US6610841B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Dec 18, 1997 |
| Grant date | Aug 26, 2003 |
| Priority date | — |
| Expiry date | Dec 18, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/549
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to nucleotide-based prodrugs and their drug-delivery applications. The nucleotide-based prodrugs of the present invention comprise a drug component covalently attached via junctional ester bond(s) to one or more nucleotide components. Release and activation of the drug component of a nucleotide-based prodrug arises from hydrolysis of the junctional ester bond joining the nucleotide component to the drug component. The active drug component may be a nucleoside analog, a nucleic acid ligand, or a non-nucleoside drug. The nucleotide component provides a means of targeting and/or anchoring the nucleotide-based prodrug to the desired tissue compartment and/or a mechanism of sustained release of the active drug, thereby providing for a more effective drug delivery system with reduced toxicity. The targeting and/or anchoring of the nucleotide-based prodrugs to the desired tissue can be achieved through several methods, including employing a nucleic acid ligand as the nucleotide component, and/or by incorporating photocrosslinkable bases into the nucleotide component, and/or by covalently bonding the nucleotide component to a macromolecular support. The invention fur…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.